Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Lineage Cell Therapeutics (LCTX) Short term Debt (2020 - 2021)

Lineage Cell Therapeutics' Short term Debt history spans 4 years, with the latest figure at $523000.0 for Q1 2021.

For Q1 2021, Short term Debt changed N/A year-over-year to $523000.0; the TTM value through Mar 2021 reached $523000.0, changed N/A, while the annual FY2020 figure was $523000.0, N/A changed from the prior year.
Short term Debt reached $523000.0 in Q1 2021 per LCTX's latest filing, roughly flat from $523000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $523000.0 in Q2 2020 to a low of $523000.0 in Q2 2020.